Suliqua

Suliqua combines insulin glargine and lixisenatide to support blood sugar control in adults with type 2 diabetes. This dual-action injectable is designed for once-daily use alongside diet and exercise. Ideal for patients seeking combined therapy in a single pen. Suitable for subcutaneous administration only.

Suliqua is used to improve blood glucose levels in adults with type 2 diabetes who are not adequately controlled with basal insulin or lixisenatide alone. It combines a long-acting insulin (insulin glargine) with a GLP-1 receptor agonist (lixisenatide) to provide both basal insulin support and post-meal glucose regulation. This combination therapy helps maintain steady blood sugar throughout the day and after meals.

Suliqua works gradually to lower blood sugar levels over time, helping to reduce spikes after meals and maintain steady glucose throughout the day. Users may notice improved energy levels and reduced symptoms of high blood sugar, such as frequent urination or excessive thirst. Effects vary by individual and are best supported by consistent diet and activity habits.

Store Suliqua in the refrigerator until first use; after opening, it can be kept at room temperature for a limited time as directed. Protect from direct heat and sunlight. Always check the pen for clarity and particles before use. Dispose of needles safely and avoid sharing pens to prevent infection or contamination.

Suliqua may interact with medications that affect blood sugar, such as oral antidiabetics, corticosteroids, or diuretics. Alcohol and certain herbal supplements can also influence glucose levels. Always inform your healthcare provider about all medications and supplements you are taking to avoid unexpected changes in blood sugar.